 |
|
UCI researchers create new strategy for highly-selective chemotherapy delivery
September 25, 2009Study points way to precisely targeted cancer treatments
Irvine, Calif. - UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs.
Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.
Using this technology, the research team demonstrated that the doxorubicin was directed almost entirely to the targeted site with virtually no uptake by other organs, including lung, kidney and heart.
Their study appears online in the International Journal of Pharmaceutics.
Their approach is based on the fact that all tissues and organs, including all tumors, are surrounded by a dense region of sugar-containing molecules called polysaccharides. Most importantly, the particular chemical composition of the polysaccharides is different in each tissue and organ of the body. The chemical compositions of the polysaccharides of tumor regions are also different from normal tissue.
The research team developed a nanocarrier system that can recognize specific types of polysaccharide, and has demonstrated effective, organ-specific delivery of nanocarriers, and their therapeutic contents, based upon this polysaccharide-targeting approach.
In their study, the researchers used a peptide derived from a protein found in the microorganism Plasmodium, which is an organism well-known for its exceptional ability to exclusively target the polysaccharides of liver following entry into the bloodstream.
The drug doxorubicin is a chemotherapeutic agent commonly used as treatment for a variety of cancers. Although it is an effective anti-cancer agent, the usefulness of doxorubicin is compromised by its serious side effects on normal tissue. When administered in a chemotherapeutic regimen, doxorubicin distributes widely in the body, including the heart, rather than specifically in tumor regions.
The serious heart damage that results from systemic administration places limits on the dosage that a patient can receive. By encapsulating doxorubicin into a liposome package and including a peptide targeting message on the carrier, Longmuir, Robertson and co-workers demonstrated that doxorubicin can be effectively delivered to the liver, and away from the heart, with a specificity of greater than 100:1.
The next step in this investigation is to test the properties of the delivery system in several experimental cancer models. Liposomes with peptides are being developed that specifically address the unique features of tumors, in order to rapidly and effectively deliver chemotherapeutic agents to tumor regions.
University of California - Irvine
Using this technology, the research team demonstrated that the doxorubicin was directed almost entirely to the targeted site with virtually no uptake by other organs, including lung, kidney and heart.
Their study appears online in the International Journal of Pharmaceutics.
Their approach is based on the fact that all tissues and organs, including all tumors, are surrounded by a dense region of sugar-containing molecules called polysaccharides. Most importantly, the particular chemical composition of the polysaccharides is different in each tissue and organ of the body. The chemical compositions of the polysaccharides of tumor regions are also different from normal tissue.
The research team developed a nanocarrier system that can recognize specific types of polysaccharide, and has demonstrated effective, organ-specific delivery of nanocarriers, and their therapeutic contents, based upon this polysaccharide-targeting approach.
In their study, the researchers used a peptide derived from a protein found in the microorganism Plasmodium, which is an organism well-known for its exceptional ability to exclusively target the polysaccharides of liver following entry into the bloodstream.
The drug doxorubicin is a chemotherapeutic agent commonly used as treatment for a variety of cancers. Although it is an effective anti-cancer agent, the usefulness of doxorubicin is compromised by its serious side effects on normal tissue. When administered in a chemotherapeutic regimen, doxorubicin distributes widely in the body, including the heart, rather than specifically in tumor regions.
The serious heart damage that results from systemic administration places limits on the dosage that a patient can receive. By encapsulating doxorubicin into a liposome package and including a peptide targeting message on the carrier, Longmuir, Robertson and co-workers demonstrated that doxorubicin can be effectively delivered to the liver, and away from the heart, with a specificity of greater than 100:1.
The next step in this investigation is to test the properties of the delivery system in several experimental cancer models. Liposomes with peptides are being developed that specifically address the unique features of tumors, in order to rapidly and effectively deliver chemotherapeutic agents to tumor regions.
University of California - Irvine
Chemotherapeutic Current Events and Chemotherapeutic News RSSFertility procedures need not delay breast cancer treatment for younger women
A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.
Duke develops nano-scale drug delivery for chemotherapy
Going smaller could bring better results, especially when it comes to cancer-fighting drugs.
Chemosensitivity of cancer cells depends on their protein dependency
Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB).
Melanoma treatment options 1 step closer
A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.
Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.
Echoes of phlogiston in stem cell biology
Before it was learned that matter burns by taking up oxygen, most chemists sought to explain combustion as the release of a mysterious substance, which they named "phlogiston".
Promise of nanodiamonds for safer gene therapy
Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others.
NIH study reveals new genetic culprit in deadly skin cancer
Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma.
Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.
First compound that specifically kills cancer stem cells found
The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all.
More Chemotherapeutic Current Events and Chemotherapeutic News Articles
 |
Antibacterial Chemotherapeutic Agents by S.L. Dax (Author) Over the past 50 years a wide variety of antibacterial substances have been discovered and synthesised, and their use in treating bacterial infection has been spectacularly successful. Today there are several general classes of antibacterial drugs, each having a well established set of uses, and together they form the mainstay of modern antibacterial chemotherapy. In search for new and improved agents, the pharmaceutical researcher needs to be well informed on many topics, including existing agents, their modes of action and pharmacology, and possible synthetic approaches. In this new book the author has brought together a wide range of information on the principal classes of antibacterial agents, and he covers, for each group, their history, mode of action, key structural... |
 |
Chemotherapeutic Targets in Parasites: Contemporary Strategies by Tag E. Mansour (Author), Joan MacKinnon Mansour (Contributor) Chemotherapeutic Targets in Parasites analyzes the critical metabolic reactions and structural features essential for parasite survival, and advocates the latest molecular strategies with which to identify effective antiparasitic agents. An introduction to the early development of parasite chemotherapy is followed by an overview of biophysical techniques and genomic and proteomic analysis. Several chapters are devoted to specific types of chemotherapeutic agents and their targets. There are sections discussing helminths; including metabolic, neuromuscular, microtubular and tegumental targets. The design of more selective and less toxic drugs is emphasized throughout. |
|
Pocket Guide to Injectable Chemotherapeutic Agents (Third Edition) b | |
|
Pocket Guide to Injectable Chemotherapeutic Agents (Fourth Edition) by Byron G. Peters (Editor) Drug information and dosages | |
 |
Burger's Medicinal Chemistry and Drug Discovery, Chemotherapeutic Agents (Volume 5) by Donald J. Abraham (Editor) This is Volume 5: Chemotherapeutic Agents, of Burger's Medicinal Chemistry and Drug Discovery, 6th Edition. This new volume contains critical new chapters on Molecular Biology of Cancer, Synthetic Anti-angiogenic Agents and Selective Toxicities. To purchase the entire 6 volume set, please refer to ISBN 0-471-37032-0. |
|
Platinum, Gold, and Other Metal Chemotherapeutic Agents: Chemistry and Biochemistry (Acs Symposium Series) by Stephen J. Lippard (Editor) | |
 |
Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells: Status and Modulation by Chemotherapeutic Drugs by Dr. Gabriele Imre (Author) The transcription factor nuclear factor kappa-B (NFkB) plays a pivotal role in the immune response but is also involved in cancer development and progression. In unstimulated cells NFkB is kept inactive in the cytoplasm by inhibitor of NFkB (IkB) proteins. Dysregulation of the pathway or activation of NFkB by chemotherapeutic agents may lead to cancer progression or drug resistance. The NFkB activation status was investigated in human lung cancer, pancreatic cancer, and hematopoietic cancer cell lines. Additionally, the potential of cytotoxic drugs in activating the NFkB signaling pathway was analyzed. Furthermore, the influence of histone deacetylase inhibitors (HDIs) on the NFkB pathway in human non-small cell lung cancer (NSCLC) cell lines was investigated. Incubation of NSCLC cells... |
 |
Cancer Chemotherapeutic Agents: Handbook of Clinical Data by M.R. Sather (Author) |
|
CHEMOTHERAPEUTIC AND OTHER STUDIES OF TYPHUS Medical Research Council, Special Report Series No. 255 by Et Al Van Den Ende (Author) | |
|
Guide to Cancer Chemotherapeutic Regimens 2002 by Val R. Adams (Author), Jody B. Sheehan (Author), Mark T. Holdsworth (Author) |
| © 2009 BrightSurf.com |